

## Supplementary information

### Tables

Table S1: Bacterial strains used in the study

Strain	Description*	Source
<i>E. coli</i> strains		
BL21(DE3)	Strain used for production of ChiUL enzymes	Invitrogen (Carlsbad, US)
DH5 $\alpha$ MCR	Strain used for general cloning	Life Technologies (Grand Island, NY, USA)
HB101	Strain used for triparental conjugation	[1]
Rosetta(DE3) pLysS	Strain used for production of CusD proteins	EMD Millipore (Darmstadt, Germany)
<i>F. johnsoniae</i> strains		
UW101 (ATCC 17061 <sup>T</sup> )	Wild type	
CJ1808	<i>chiA</i> disruption mutant; (Em <sup>r</sup> )	[2]
CJ1827	<i>rpsL2</i> ; (Sm <sup>r</sup> ) “wild type” strains for construction of all deletion mutants	[3]
CJ2018	<i>rpsL2</i> $\Delta$ <i>cusD</i> <sub>II</sub> (Fjoh_4561); (Sm <sup>r</sup> )	This study
CJ2086	<i>rpsL2</i> $\Delta$ <i>cusC</i> <sub>I</sub> (Fjoh_4559); (Sm <sup>r</sup> )	This study
CJ2121	<i>rpsL2</i> $\Delta$ <i>cusD</i> <sub>I</sub> (Fjoh_4558); (Sm <sup>r</sup> )	This study
CJ2156	<i>rpsL2</i> $\Delta$ <i>cusD</i> <sub>I</sub> $\Delta$ <i>cusD</i> <sub>II</sub> ; (Sm <sup>r</sup> )	This study
CJ2340	<i>rpsL2</i> $\Delta$ <i>cusC</i> <sub>II</sub> (Fjoh_4562); (Sm <sup>r</sup> )	This study
CJ2349	<i>rpsL2</i> $\Delta$ ( <i>cusC</i> <sub>I</sub> - <i>cusD</i> <sub>II</sub> ); (Sm <sup>r</sup> )	This study
CJ2350	<i>rpsL2</i> $\Delta$ <i>chiB</i> (Fjoh_4560); (Sm <sup>r</sup> )	This study
CJ2453	<i>rpsL2</i> $\Delta$ ( <i>cusS</i> - <i>cusR</i> ); (Sm <sup>r</sup> )	This study
CJ2456	<i>rpsL2</i> $\Delta$ Fjoh_4556; (Sm <sup>r</sup> )	This study
CJ2457	<i>rpsL2</i> $\Delta$ Fjoh_4565; (Sm <sup>r</sup> )	This study
CJ2463	<i>rpsL2</i> $\Delta$ <i>nagB</i> (Fjoh_4557); (Sm <sup>r</sup> )	This study
CJ2590	<i>rpsL2</i> $\Delta$ <i>cusC</i> <sub>I</sub> $\Delta$ <i>cusC</i> <sub>II</sub> ; (Sm <sup>r</sup> )	This study
CJ2676	<i>rpsL2</i> $\Delta$ ( <i>cusC</i> <sub>II</sub> - <i>cusD</i> <sub>II</sub> ); (Sm <sup>r</sup> )	This study
CJ2677	<i>rpsL2</i> $\Delta$ ( <i>cusC</i> <sub>I</sub> - <i>cusD</i> <sub>I</sub> ); (Sm <sup>r</sup> )	This study
CJ2679	<i>rpsL2</i> $\Delta$ ( <i>cusC</i> <sub>I</sub> - <i>cusD</i> <sub>I</sub> ) $\Delta$ ( <i>cusC</i> <sub>II</sub> - <i>cusD</i> <sub>II</sub> ); (Sm <sup>r</sup> )	This study

\*Antibiotic resistance phenotypes: ampicillin, Ap<sup>r</sup>; erythromycin, Em<sup>r</sup>; kanamycin, Km<sup>r</sup>; streptomycin, Sm<sup>r</sup>; tetracycline, Tc<sup>r</sup>. Unless indicated otherwise, the antibiotic resistance phenotypes are those expressed in *E. coli*. The antibiotic resistance phenotypes given in parentheses are those expressed in *F. johnsoniae* but not in *E. coli*

Table S2: Plasmids used in this study

Plasmid	Description*	Source
pCP23	<i>E. coli</i> / <i>F. johnsoniae</i> shuttle vector; Ap <sup>r</sup> (Tc <sup>r</sup> )	[4]
pDE01	1.7 kbp region upstream of <i>nagB</i> amplified with primers 1626 and 1627 and cloned into XbaI and SalI sites of pRR51; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pDE02	Construct used to delete <i>nagB</i> ; 1.7 kbp region downstream of <i>nagB</i> amplified with primers 1628 and 1629 and cloned into SalI and SphI sites of pDE01; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pETite N-His	Expression plasmid, including an N-terminal His <sub>6</sub> -tag and TEV protease cleavage site; (Km <sup>r</sup> )	Lucigen
pLW01	pCP23 carrying <i>cusD</i> <sub>I</sub> ; Ap <sup>r</sup> (Tc <sup>r</sup> )	This study
pNIC-CH	Expression plasmid, including a C-terminal His <sub>6</sub> -tag; (Km <sup>r</sup> )	Addgene
pRK2013	Helper plasmid for triparental conjugation; IncP Tra <sup>+</sup> Km <sup>r</sup>	[5]

pRR51	<i>rpsL</i> -containing suicide vector for construction of deletions; Ap <sup>r</sup> (Em <sup>r</sup> )	[3]
pSSK05	pCP23 carrying <i>chiA</i> ; Ap <sup>r</sup> (Tc <sup>r</sup> )	[2]
pSSK08	1.8 kbp region downstream of <i>cusD<sub>II</sub></i> amplified with primers 1055 and 1056 and cloned into BamHI and Sall sites of pRR51; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pSSK09	Construct used to delete <i>cusD<sub>II</sub></i> ; 1.3 kbp region upstream of <i>cusD<sub>II</sub></i> amplified with primers 1057 and 1058 and cloned into Sall and SphI sites of pSSK08; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pSSK13	1.7 kbp region downstream of <i>cusD<sub>I</sub></i> amplified with primers 1166 and 1167 and cloned into XbaI and Sall sites of pRR51; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pSSK15	1.5 kbp region downstream of <i>cusC<sub>I</sub></i> amplified with primers 1170 and 1052 and cloned into XbaI and Sall sites of pRR51; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pSSK17	Construct used to delete <i>cusC<sub>I</sub></i> ; 1.8 kbp region upstream of <i>cusC<sub>I</sub></i> amplified with primers 1053 and 1054 and cloned into Sall and SphI sites of pSSK15; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pSSK18	Construct used to delete <i>cusD<sub>I</sub></i> ; 1.7 kbp region upstream of <i>cusD<sub>I</sub></i> amplified with primers 1168 and 1169 and cloned into Sall and SphI sites of pSSK13; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pSSK29	1.9 kbp region downstream of <i>cusC<sub>II</sub></i> amplified with primers 1250 and 1251 and cloned into XbaI and Sall sites of pRR51; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pSSK33	Construct used to delete <i>cusC<sub>II</sub></i> ; 1.8 kbp region upstream of <i>cusC<sub>II</sub></i> amplified with primers 1252 and 1253 and cloned into Sall and SphI sites of pSSK29; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pSSK38	1.5 kbp region upstream of <i>chiB</i> amplified with primers 1423 and 1424 and cloned into BamHI and Sall sites of pRR51; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pSSK40	Construct used to delete <i>chiB</i> ; 1.6 kbp region downstream of <i>chiB</i> amplified with primers 1425 and 1426 and cloned into Sall and SphI sites of pSSK38; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pSSK49	1,518-bp NheI-XhoI fragment spanning <i>cusD<sub>I</sub></i> amplified with primer 1561 and 1562 and inserted into pET28a	This study
pSSK50	1,461-bp NheI-XhoI fragment spanning <i>cusD<sub>II</sub></i> amplified with primer 1563 and 1564 and inserted into pET28a	This study
pYT248	2.1 kbp region upstream of Fjoh_4556 amplified with primers 1622 and 1623 and cloned into BamHI and Sall sites of pRR51; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pYT249	2.0 kbp region upstream of <i>cusS</i> amplified with primers 1630 and 1631 and cloned into BamHI and Sall sites of pRR51; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pYT250	1.9 kbp region upstream of Fjoh_4565 amplified with primers 1634 and 1635 and cloned into BamHI and Sall sites of pRR51; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pYT255	Construct used to delete Fjoh_4556; 2.0 kbp region downstream of Fjoh_4556 amplified with primers 1624 and 1625 and cloned into Sall and SphI sites of pYT248; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pYT256	Construct used to delete <i>cusS - cusR</i> ; 1.8 kbp region downstream of <i>cusR</i> amplified with primers 1632 and 1633 and cloned into Sall and SphI sites of pYT249; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pYT257	Construct used to delete Fjoh_4565; 1.8 kbp region downstream of Fjoh_4565 amplified with primers 1636 and 1637 and cloned into Sall and SphI sites of pYT250; Ap <sup>r</sup> (Em <sup>r</sup> )	This study
pYT259	pCP23 carrying <i>cusS - cusR</i> ; Ap <sup>r</sup> (Tc <sup>r</sup> )	This study
pYT260	pCP23 carrying Fjoh_4565; Ap <sup>r</sup> (Tc <sup>r</sup> )	This study
pYT351	pCP23 carrying <i>cusC<sub>I</sub> - cusD<sub>I</sub></i> ; Ap <sup>r</sup> (Tc <sup>r</sup> )	This study
pYT352	pCP23 carrying <i>cusC<sub>II</sub> - cusD<sub>II</sub></i> ; Ap <sup>r</sup> (Tc <sup>r</sup> )	This study
pYT353	pCP23 carrying <i>cusC<sub>I</sub></i> ; Ap <sup>r</sup> (Tc <sup>r</sup> )	This study

\*Antibiotic resistance phenotypes: ampicillin, Ap<sup>r</sup>; erythromycin, Em<sup>r</sup>; kanamycin, Km<sup>r</sup>; streptomycin, Sm<sup>r</sup>; tetracycline, Tc<sup>r</sup>. Unless indicated otherwise, the antibiotic resistance phenotypes are those expressed in *E. coli*. The antibiotic resistance phenotypes given in parentheses are those expressed in *F. johnsoniae* but not in *E. coli*.

Table S3: Primers used in this study

Primers	Sequence and Description
ChiA_F_F	5' TTAAGAAGGAGATATACTATGAAAGTTGTTGGTTATTATGCCCAGTGG 3'; forward primer used to clone ChiA_F (Fjoh_4555); LIC overhang underlined
ChiA_F_R	GTAATAGCAGTGAACCTGAGCAAAGCAGCGCACCATCATCACCACCATT 3'; reverse primer used to clone ChiA_F (Fjoh_4555); LIC overhang underlined
ChiA_N_F	5' TTAAGAAGGAGATATACTATGAAAGTTGTTGGTTATTATGCCCAGTGG 3'; forward primer used to clone ChiA_N (Fjoh_4555); LIC overhang underlined
ChiA_N_R	GATACCAGCTTTGGTAGCGTGGTTGCGCACCATCATCACCACCATT 3'; reverse primer used to clone ChiA_N (Fjoh_4555); LIC overhang underlined
ChiA_M_F	5' TTAAGAAGGAGATATACTATGGGTAGCGTGGTTCCGGGTAC 3'; forward primer used to clone ChiA_M (Fjoh_4555); LIC overhang underlined
ChiA_M_R	CAACCGTGAGCACCACATCGTTTTATTGCGCACCATCATCACCACCATT 3'; reverse primer used to clone ChiA_M (Fjoh_4555); LIC overhang underlined
ChiA_C_F	5' TTAAGAAGGAGATATACTATGGTTGTGATTAAGCAACCGACAATAAAAAG 3'; forward primer used to clone ChiA_C (Fjoh_4555); LIC overhang underlined
ChiA_C_R	GTAATAGCAGTGAACCTGAGCAAAGCAGCGCACCATCATCACCACCATT 3'; reverse primer used to clone ChiA_C (Fjoh_4555); LIC overhang underlined
GH20_F	5' TTAAGAAGGAGATATACTATGCAGATGCAGAAAAGAACAGCTGAATC 3'; forward primer used to clone GH20 (Fjoh_4556); LIC overhang underlined
GH20_R	CGTTTATGAAAGCCTGAAAAAAGTATTGCGCACCATCATCACCACCATT 3'; reverse primer used to clone GH20 (Fjoh_4556); LIC overhang underlined
ChiB_F	5' TTAAGAAGGAGATATACTATGACCAGCGAAAAAGAAAATAACCCGGAAG 3'; forward primer used to clone ChiB (Fjoh_4560); LIC overhang underlined
ChiB_R	CAAAACCAGCGGTATGTGTGGCAACGCGCACCATCATCACCACCATT 3'; reverse primer used to clone ChiB (Fjoh_4560); LIC overhang underlined
CusD <sub>I</sub> _F	5' CATCATCACCACCATCAGGAGAACCTGTACTTCCAGGGCAATGGTATTACACTTCTGATTTG 3'; forward primer used to clone CusD <sub>I</sub> (Fjoh_4558); LIC overhang and TEV site underlined
CusD <sub>I</sub> _R	5' GTGGCGCGCTCTATTAGAAATTCGAGCATTACATCC 3'; reverse primer used to clone CusD <sub>I</sub> (Fjoh_4558); LIC overhang underlined
CusD <sub>II</sub> _F1	5' CATCATCACCACCATCAGGAGAACCTGTACTTCCAGGGCCTGATAAAGGATCCGGTTGCG 3'; forward primer used to clone CusD <sub>II</sub> (Fjoh_4561) residues 26-505; LIC overhang and TEV site underlined
CusD <sub>II</sub> _F2	5' CATCATCACCACCATCAGGAGAACCTGTACTTCCAGGGCCAAATCCTG CAGGTCAGCTTAC 3'; forward primer used to clone CusD <sub>II</sub> (Fjoh_4561) residues 35-505; LIC overhang and TEV site underlined
CusD <sub>II</sub> _R	5' GTGGCGCGCTCTATTAGTTTACATCCACCAAACCTTAC 3'; reverse primer used to clone CusD <sub>II</sub> (Fjoh_4561); LIC overhang underlined
1052	5' GCTAGGTCGACACAGGTGATGCAAGAAATGCAGGC 3'; reverse primer used in construction of pSSK15; SalI site underlined
1053	5' GCTAGGTCGACTTTTACCTGTGCAAGCGAAACCTG 3'; forward primer used in construction of pSSK17; SalI site underlined
1054	5' GCTAGGCATGCGCTCCTGCAAGTCAGGCAAGTATT 3'; reverse primer used in construction of pSSK17; SphI site underlined
1055	5' GCTAGGGATCCTTTTACCTGTGCAAGCGAAACCTG 3'; forward primer used in construction of pSSK08; BamHI site underlined
1056	5' GCTAGGTCGACGCTCCTGCAAGTCAGGCAAGTATT 3'; reverse primer used in construction of pSSK08; SalI site underlined
1057	5' GCTAGGTCGACTGTAAGCTGACCTGCAGGATTTGG 3'; forward primer used in construction of pSSK09; SalI site underlined
1058	5' GCTAGGCATGCAATGCACCGGGAGCTTACAAGAAC 3'; reverse primer used in construction of pSSK09; SphI site underlined
1166	5' GCTAGTCTAGATACAATTTTCGATATCCTCCTGCCC 3'; forward primer used in construction of pSSK13; XbaI site underlined
1167	5' GCTAGGTCGACGGAGTTTCTAAATTGGGCGGACCA 3'; reverse primer used in construction of pSSK13; SalI site underlined
1168	5' GCTAGGTCGACGGCGAGTAACAAAGTACAAATAGTTGCTTT 3'; forward primer used in construction of pSSK18; SalI site underlined
1169	5' GCTAGGCATGCTGGTTGTCGATTGCTTCTAGATACAGTTAT 3'; reverse primer used in construction of pSSK18; SphI site underlined
1170	5' GCTAGTCTAGACTGAGCAGTACCGCCCATATTCCA 3'; forward primer used in construction of pSSK15; XbaI site underlined
1250	5' GCTAGGTCGACGAGCAAATGGAGTTGTAATACAGGA 3'; reverse primer used in construction of pSSK29; SalI site underlined

---

1251	5' <u>GCTAGTCTAGA</u> AGTTTACATCCCAACCTTACCAG3'; forward primer used in construction of pSSK29; XbaI site underlined
1252	5' GCTAGGCATGCCTGCTGCAAATTCCTAAAAGC 3'; reverse primer used in construction of pSSK33; SphI site underlined
1253	5' <u>GCTAGGTCGAC</u> AGCAGATGCCTGAATCGTATACATACC 3'; forward primer used in construction of pSSK33; SalI site underlined
1423	5' <u>GCTAGGGATCC</u> TTTACTCAATTATGTATGTCTGGAGAC 3'; forward primer used in construction of pSSK38; BamHI site underlined
1424	5' GCTAGGTCGACAAGGATGCCTAATAAGGCTTTATTTTT 3'; reverse primer used in construction of pSSK38; SalI site underlined
1425	5' <u>GCTAGGTCGACT</u> ACAAGACTTCAGGCATGTGCGGT 3'; forward primer used in construction of pSSK40; SalI site underlined
1426	5' <u>GCTAGGCATGCT</u> ATAATAATTAAGTCATTTCTCTTTG 3'; reverse primer used in construction of pSSK40; SphI site underlined
1512	5' <u>GCTAGGGTACC</u> GGAAGCTGGCTCAGGATTCTT 3'; forward primer used in construction of pYT351 and pYT353; KpnI site underlined
1515	5' <u>GCTAGGCATGC</u> CTGCTGTACCATTGCTAACC 3'; reverse primer used in construction of pLW01 and pYT351; SphI site underlined
1561	5' <u>GCTAGGCTAGC</u> ACAGATAATTTGAAGACATTAATACT 3'; forward primer used in construction of pSSK49; NheI site underlined
1562	5' <u>GCTAGCTCGA</u> GTTAGAAAATTCGGAGCATTTACATCCCA 3'; reverse primer used in construction of pSSK49; XhoI site underlined
1563	5' <u>GCTAGGCTAGC</u> ACAGAAAAATTTGACGAACTGATAAAG 3'; forward primer used in construction of pSSK50; NheI site underlined
1564	5' <u>GCTAGCTCGA</u> GTTAGTTTACATCCCAACCTTACC 3'; reverse primer used in construction of pSSK50; XhoI site underlined
1622	5' <u>GCTAGGGATCC</u> GAAAGCTTCGGTAATTGTAGCACAGG 3'; forward primer used in construction of pYT248; BamHI site underlined
1623	5' <u>GCTAGGTCGAC</u> TCTTTTTGCATTTGAGCATTGTC 3'; reverse primer used in construction of pYT248; SalI site underlined
1624	5' <u>GCTAGGTCGAC</u> AAAGATCATGCTGACGTAGAGTTG 3'; forward primer used in construction of pYT255; SalI site underlined
1625	5' <u>GCTAGGCATGCG</u> CATTTTCGTAATCAACTGTAACAT 3'; reverse primer used in construction of pYT255; SphI site underlined
1626	5' <u>GCTAGTCTAGA</u> GTACTTTGTTACTCGCCGCTGTG 3'; forward primer used in construction of pDE01; XbaI site underlined
1627	5' <u>GCTAGGTCGAC</u> GCGCTTTATAACTGATATCAGG 3'; reverse primer used in construction of pDE01; SalI site underlined
1628	5' <u>GCTAGGTCGAC</u> AGAGAATCTGGGTTAGAGCCGAAG 3'; forward primer used in construction of pDE02; SalI site underlined
1629	5' <u>GCTAGGCATGCG</u> GCAAGTTCTGTCCACATTGTAGC 3'; reverse primer used in construction of pDE02; SphI site underlined
1630	5' <u>GCTAGGGATCC</u> TCCTGTCTTCTAAAATCTCTGCGG 3'; forward primer used in construction of pYT249; BamHI site underlined
1631	5' <u>GCTAGGTCGAC</u> GTAGCTTCCCCAAAACCATATATGA 3'; reverse primer used in construction of pYT249; SalI site underlined
1632	5' <u>GCTAGGTCGAC</u> CAAATTCAGTCGTACAGATTCTTA 3'; forward primer used in construction of pYT256; SalI site underlined
1633	5' <u>GCTAGGCATGCG</u> GCTAAGTAAAAGGGCCAAAGGT 3'; reverse primer used in construction of pYT256 and pYT260; SphI site underlined
1634	5' <u>GCTAGGGATCC</u> TTTACTCTCAACTTTTTACGATGGG 3'; forward primer used in construction of pYT250; BamHI site underlined
1635	5' <u>GCTAGGTCGAC</u> AAACTGTCCCCATTTGGTTTGAAC 3'; reverse primer used in construction of pYT250; SalI site underlined
1636	5' <u>GCTAGGTCGAC</u> TGAAAAACAAGGAATCAGCCAC 3'; forward primer used in construction of pYT257; SalI site underlined
1637	5' <u>GCTAGGCATGCG</u> GATAAGGTTTACGAAAAAATGCT 3'; reverse primer used in construction of pYT257; SphI site underlined
1650	5' <u>GCTAGGGATCC</u> TTGAATAATAACTTACTCCCGGC 3'; forward primer used in construction of pYT259; BamHI site underlined
1651	5' <u>GCTAGGCATGCC</u> CAACTACCTTATTTATCAACAATGTG 3'; reverse primer used in construction of pYT259; SphI site underlined
1652	5' <u>GCTAGGGATCC</u> CGATAACCACAAAAGGCGATTAC 3'; forward primer used in construction of pYT260; BamHI site underlined

---

1871	5' <u>GCTAGGGTAC</u> CCTACACAACCTGTTGGAGGAAGA 3'; forward primer used in construction of pLW01; KpnI site underlined
1955	5' GCTAGGGT <u>ACC</u> ATCATTAAAGTAAGCACCCCATCG 3'; forward primer used in construction of pYT352; KpnI site underlined
1956	5' GCTAGGCATGCCCTTATCAGGCATAACTATATTTTAGG 3'; reverse primer used in construction of pYT352; SphI site underlined
1957	5' GCTAGGCATG <u>CC</u> GGCGAGTAAACAAAGTACAAATAG 3'; reverse primer used in construction of pYT353; SphI site underlined

Table S4: X-ray Data Collection and Refinement Statistics

	CusD <sub>I</sub> (Fjoh_4558)	CusD <sub>II</sub> (Fjoh_4561)
PDB	5J90	5J5U
Resolution range (Å)	36.57 – 1.393	44.49 – 2.3
Space group	P 21 21 21	P 1
Unit cell (Å)	79.33, 112.14, 121.57 $\alpha=\beta=\gamma=90^\circ$	82.71 82.89 93.91 $\alpha=66.4^\circ, \beta=78.3^\circ \gamma=67.6^\circ$
Total reflections	1693675 (129785)	357070 (35307)
Unique reflections	215491 (21033)	91093 (9016)
Multiplicity	7.9 (6.2)	3.9 (3.9)
Completeness (%)	99.81 (98.30)	97.26 (96.68)
Mean I/sigma(I)	26.56 (4.63)	7.88 (4.14)
Wilson B-factor	11.53	22.6
$R_{\text{merge}}$	0.05585 (0.3396)	0.123 (0.3061)
$R_{\text{meas}}$	0.05968	0.1424
CC1/2	0.998 (0.941)	0.986 (0.909)
CC*	0.999 (0.985)	0.996 (0.976)
$R_{\text{work}}$	0.1503 (0.1911)	0.2139 (0.2566)
$R_{\text{free}}$	0.1673 (0.2213)	0.2626 (0.3454)
Number of non-hydrogen atoms	9149	14777
macromolecules	7591	14157
ligand (ethylene glycol)	44	0
water	1514	620
Protein residues	964	1806
RMS bonds (Å)	0.006	0.009
RMS angles (°)	1.08	1.14
Ramachandran favored (%)	97	97
Ramachandran allowed (%)	3	3
Ramachandran outliers (%)	0	0
Clashscore	0.8	3.1
Average B-factor	15.7	26
macromolecules	13.5	26
ligands (ethylene glycol)	24.1	
solvent	26.4	25.3

Values in parenthesis are for the highest resolution shell

## Figures




Figure S1: Chitin utilization of wild type *F. johnsoniae* and mutants. Chitin utilization was observed as the disappearance of insoluble chitin at the bottom of the test tubes, and growth was observed as increased turbidity throughout the culture. The *chiA* mutant was used as a negative control that exhibited no growth and no chitin conversion. Cells (0.02 ml,  $OD_{600}=1.0$ ) were introduced into 10 ml of Stanier medium supplemented with 0.05% chitin in 150 mm by 25 mm test tubes and incubated at 25°C. Growth experiments were performed in duplicate (with the same results) and one set of data is shown.




Figure S2: Western blot immunodetection of ChiA. *F. johnsoniae* wild type and mutant cells were grown overnight in motility medium at 25°C with shaking. Cells and supernatants (spent media) were separated by centrifugation. For whole cells, 10  $\mu$ g cell protein was loaded on gels. For secreted proteins, the amount of spent medium that contained 10  $\mu$ g cell protein before cell removal was loaded. Western blot analyses were performed using antibodies against ChiA at 1: 5,000 dilution. pYT259 expresses the two component signal transduction proteins CusS and CusR, and pSSK05 expresses ChiA. The observation of ChiA as a ~95 kDa band (the expected size is 169 kDa) is consistent with previous studies, which used the same antibodies as in

the current study, raised against a part of the N-terminal region of the protein [2]. The ChiUL does not encode proteases, and we assume that ChiA<sub>F</sub> is proteolytically cleaved by secreted proteases during growth, similar to how the well-studied *Serratia marcescens* chitinases are susceptible to cleavage by endogenously produced proteases, whereby chitinolytic activity is decreased [6, 7]. ChiA<sub>F</sub> does not exhibit detectable auto-lytic activities (no degradation observed by SDS-PAGE after incubation at 22°C for two days in 50 mM sodium phosphate, pH 6.5). Given that ChiA<sub>F</sub> is dramatically more active on chitin as full-length protein compared to the individual GH18 domains (ChiA<sub>N</sub> and ChiA<sub>C</sub>, singly or combined), it is likely that full-length ChiA is responsible for chitin utilization by *F. johnsoniae*. Further, the strong affinity of the middle region of ChiA (ChiA<sub>M</sub>, Figure 6) to chitin crystals, suggests that ChiA<sub>F</sub> is in intimate contact with the substrate during degradation. Note that only soluble fractions were analyzed in the Western blot immunodetection experiments. It is possible that ChiA<sub>F</sub>, protected from proteases while bound to its insoluble substrate, was not detected for this reason.




Figure S3: Growth curves of cells carrying pYT353 (*cusC<sub>I</sub>*) on chitin (A) and glucose (B). For growth on chitin, cells (0.1 ml,  $OD_{600}=1.0$ ) were introduced into 50 ml of Stanier medium supplemented with 0.05% chitin in 250-ml flasks, and incubated with shaking at 25°C. Growth presented as log ( $\mu\text{g}$  cell protein/ml). For growth on glucose, cells (0.1 ml,  $OD_{600}=1.0$ ) were introduced into 50 ml of Stanier medium supplemented with 0.1% glucose in 250-ml side-arm flasks and incubated with shaking at 25°C. Growth presented as log (Klett Units). Growth curves were performed in triplicate and error bars indicate standard deviations. pYT353 is derived from pCP23, which has a copy number of approximately 10 in *F. johnsoniae*.




Figure S4: Growth curves of wild type cells and predicted cytoplasmic inner membrane sugar transporter mutants. *pYT260* expresses the predicted cytoplasmic membrane sugar transporter *Fjoh\_4565*. Cells (0.1 ml,  $OD_{600}=1.0$ ) were introduced into 50 ml of medium in 250-ml side-arm flasks and incubated with shaking at 25°C. A: Stanier medium supplemented with 0.1% glucose as sole source of carbon and energy. B: Stanier medium supplemented with 0.1% N-acetylglucosamine as sole source of carbon and energy. C: CYE medium. Growth presented as log (Klett Units). Growth curves were performed in triplicate and error bars indicate standard deviations.






Figure S5: Binding analysis of the CusD proteins to insoluble polysaccharides. Lanes are labelled as C for control (protein incubated in buffer), S for soluble proteins after incubation with polysaccharides, and B for bound proteins, where the polysaccharides had been washed once in buffer and subsequently resuspended in SDS-PAGE loading buffer to release bound proteins. Bovine serum albumin (BSA) was used as a non-binding reference protein.



Figure S6: Section of a structural alignment of *Serratia marcescens* chitinases (ChiA, B and C) to which the ChiUL chitinase domains were added. The red box highlights the  $\alpha\beta$ -insert region. The characteristic catalytic motif, DXXDXDXE, is indicated by a black bar. The alignment was prepared using Clustal Omega [8], manually edited and displayed using BioEdit.




Figure S7: pH profiles for all enzymes. A: ChiA\_N, B: ChiA\_C, C: ChiB, D: GH20. The buffers (50 mM) used were: citrate (closed squares), sodium phosphate (open squares), tris (closed circles), MES (open circles), sodium acetate (closed triangles), Bis-Tris (open triangles), and sodium carbonate (crosses). The substrate was chitotetraose and the incubation temperature was 25°C. Data points are the average of duplicate experiments and error bars represent the standard error of the mean.

## References

1. Bolivar F, Backman K: **Plasmids of *Escherichia coli* as cloning vectors.** *Methods Enzymol* 1979, **68**:245-267.
2. Kharade SS, McBride MJ: ***Flavobacterium johnsoniae* chitinase ChiA is required for chitin utilization and is secreted by the type IX secretion system.** *J Bacteriol* 2014, **196**:961-970.
3. Rhodes RG, Pucker HG, McBride MJ: **Development and use of a gene deletion strategy for *Flavobacterium johnsoniae* to identify the redundant gliding motility genes *remF*, *remG*, *remH*, and *remI*.** *J Bacteriol* 2011, **193**:2418-2428.
4. Agarwal S, Hunnicutt DW, McBride MJ: **Cloning and characterization of the *Flavobacterium johnsoniae* (*Cytophaga johnsonae*) gliding motility gene, *gldA*.** *Proc Natl Acad Sci USA* 1997, **94**:12139-12144.
5. Figurski DH, Helinski DR: **Replication of an origin-containing derivative of plasmid RK2 dependent on a plasmid function provided in trans.** *Proc Natl Acad Sci USA* 1979, **76**:1648-1652.
6. Suzuki K, Sugawara N, Suzuki M, Uchiyama T, Katouno F, Nikaidou N, Watanabe T: **Chitinases A, B, and C1 of *Serratia marcescens* 2170 produced by recombinant *Escherichia coli*: enzymatic properties and synergism on chitin degradation.** *Biosci Biotechnol Biochem* 2002, **66**:1075-1083.
7. Suzuki K, Taiyoji M, Sugawara N, Nikaidou N, Henrissat B, Watanabe T: **The third chitinase gene (*chiC*) of *Serratia marcescens* 2170 and the relationship of its product to other bacterial chitinases.** *Biochem J* 1999, **343**:587-596.
8. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Soding J, et al: **Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega.** *Mol Syst Biol* 2011, **7**:539.